Funding for this research was provided by:
Ironwood Pharmaceuticals (NA)
Text and Data Mining valid from 2019-06-21
Received: 30 April 2019
Accepted: 11 June 2019
First Online: 21 June 2019
Ethics approval and consent to participate
: This multicenter study was approved by ethics committees at each site, and all participants provided written informed consent.
: Not applicable.
: Nicola Dalbeth received speaking fees from Pfizer, Horizon, Janssen, and AbbVie; consulting fees from Horizon, AstraZeneca, Dyve Biosciences, Hengrui, and Kowa; and research funding from Amgen and AstraZeneca on unrelated projects. Christopher Frampton declares that he has no competing interests. Maple Fung was a former employee of Ardea/AstraZeneca. Scott Baumgartner was a former employee of Ardea/AstraZeneca. Savvas Nicolaou (institutional) has a master research agreement with Siemens. Hyon K Choi received consulting fees from Takeda, Selecta, Kowa, and Horizon, and research grants from Selecta and Horizon on unrelated projects.